StockData
Beam Therapeutics Inc. logo

Beam Therapeutics Inc. (BEAM) stock

BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/304% below fair value
$22.83−1.20 (-4.99%)

Close on Nov 13, 2026Market cap $2.36BP/E –Yield –

Beam Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Beam Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$355.78M. For fiscal 2025 it was -$361.40M. The highest annual figure on record is -$71.65M in fiscal 2019.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$361.40M–
FY2024Dec 31, 2024-$393.64M–
FY2023Dec 31, 2023-$156.47M–
FY2022Dec 31, 2022-$324.33M–
FY2021Dec 31, 2021-$385.01M–
FY2020Dec 31, 2020-$128.03M–
FY2019Dec 31, 2019-$71.65M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$121.14M–
Q1 FY2026Mar 31, 2026-$101.61M–
Q4 FY2025Dec 31, 2025-$11.78M–
Q3 FY2025Sep 30, 2025-$121.25M–
Q2 FY2025Jun 30, 2025-$114.61M–
Q1 FY2025Mar 31, 2025-$113.76M–
Q4 FY2024Dec 31, 2024-$94.59M-168.4%
Q3 FY2024Sep 30, 2024-$101.03M–
Q2 FY2024Jun 30, 2024-$99.32M–
Q1 FY2024Mar 31, 2024-$98.70M–
Q4 FY2023Dec 31, 2023$138.22M–
Q3 FY2023Sep 30, 2023-$103.08M–
Q2 FY2023Jun 30, 2023-$97.33M–
Q1 FY2023Mar 31, 2023-$94.28M–
Q4 FY2022Dec 31, 2022-$85.04M–
Q3 FY2022Sep 30, 2022-$87.83M–
Q2 FY2022Jun 30, 2022-$78.55M–
Q1 FY2022Mar 31, 2022-$72.91M–
Q4 FY2021Dec 31, 2021-$60.85M–
Q3 FY2021Sep 30, 2021-$67.88M–
Q2 FY2021Jun 30, 2021-$57.31M–
Q1 FY2021Mar 31, 2021-$198.98M–
Q4 FY2020Dec 31, 2020-$39.53M–
Q3 FY2020Sep 30, 2020-$36.10M–
Q2 FY2020Jun 30, 2020-$25.14M–
Q1 FY2020Mar 31, 2020-$27.26M–

More Beam Therapeutics figures

See a number that looks wrong?